Mehdi H. Hamadani, MD

Professor and Cancer Center Scholar Endowed Chair; Chief, Section of Hematologic Malignancies; Scientific Director, CIBMTR; Division of Hematology and Oncology; Co-Associate Director of Clinical Research

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is A a professor of medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma.

(Khaliq A, Wesson W, Logan E, Tabak C, Mushtaq MU, Lin T, Baranda J, Shune L, Abdallah AO, McGuirk J, Hamadani M, Ahmed N.) Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):e344-e349 PMID: 38910060 06/24/2024
Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

(Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M, Kharfan-Dabaja MA.) Transplant Cell Ther. 2024 Sep;30(9):832-843 PMID: 38972511 07/08/2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry.

(Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, Hamadani M, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE.) Transplant Cell Ther. 2024 Sep;30(9):917.e1-917.e12 PMID: 38944153 SCOPUS ID: 2-s2.0-85199289175 06/30/2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.

(Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N.) Transplant Cell Ther. 2024 Sep;30(9):876-884 PMID: 38871056 06/14/2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

(Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

(Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA.) Clin Infect Dis. 2024 Aug 16;79(2):542-554 PMID: 38801746 PMCID: PMC11327798 SCOPUS ID: 2-s2.0-85201391712 05/27/2024
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature.

(Kim NH, Hamadani M, Abedin S.) Expert Opin Investig Drugs. 2024 Aug;33(8):791-799 PMID: 38973782 PMCID: PMC11305901 SCOPUS ID: 2-s2.0-85198098956 07/08/2024
Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.

(Ahmed G, Furqan F, Nasrollahi E, Hamadani M.) Expert Rev Anticancer Ther. 2024 Aug;24(8):705-715 PMID: 38809821 05/29/2024
CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma.

(Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M.) Blood Adv. 2024 Jul 10 PMID: 38985302 07/10/2024
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

(Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M.) Blood Cancer J. 2024 Jul 08;14(1):108 PMID: 38977682 PMCID: PMC11231252 SCOPUS ID: 2-s2.0-85197736867 07/09/2024
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.

(Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S.) Br J Haematol. 2024 May 26 PMID: 38797526 05/27/2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

(Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK.) Front Immunol. 2024;15:1405452 PMID: 38915401 PMCID: PMC11194690 SCOPUS ID: 2-s2.0-85196643451 06/25/2024